Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861826 | 0.92 | HSD17B10 (0.41) | PTGS2PTPN1KDM4EUSP2HSD17B10 | |
| SCHEMBL4859624 | 0.89 | PTGS2 (0.46) | PTGS2PTGS1KDM4EALDH1A1RXFP1 | |
| SCHEMBL6141813 | 0.88 | PTGS2 (0.51) | PTGS2PTGS1KDM4E | |
| SCHEMBL6141923 | 0.88 | PTGS2 (0.51) | PTGS2PTGS1KDM4E | |
| SCHEMBL2949905 | 0.87 | KDM4E (0.41) | KDM4EUSP2HSD17B10L3MBTL1ALDH1A1 | |
| SCHEMBL4862252 | 0.86 | PTGS2 (0.42) | PTGS2PTGS1PTPN1USP2HSD17B10 | |
| SCHEMBL4862273 | 0.86 | ALDH1A1 (0.52) | KDM4EUSP2HSD17B10L3MBTL1ALDH1A1 | |
| SCHEMBL4854822 | 0.86 | KDM4E (0.47) | PTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL4854799 | 0.86 | PTPN1 (0.41) | PTGS2PTGS1PTPN1KDM4EUSP2 | |
| SCHEMBL4855877 | 0.83 | PTPN1 (0.39) | PTGS2PTGS1PTPN1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | claimed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | claimed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | PTGS2 1957/4885PTGS1 1116/4885PTPN1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.